Adam M Kinsey

Ventrix, Inc.

$3,583,667

Attributed

$5,340,638

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.4M · FY2011–24

$2M$1.5M$1M$500K$0

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

Funding mix

By agency

NIH$5,340,638 · 4

By mechanism

R44$4,052,165 · 2

R43$1,288,473 · 2

Top collaborators

Karen L Christman4 shared
Nabil Dib1 shared

Most similar at Ventrix, Inc.

Same institution · by research overlap

Nabil Dib$165,643

Others in their field

Top investigators on “Regenerative”

Prasant Mohapatra · University Of California At Davis$57,033,632
Lee Hamm · Tulane University Of Louisiana$42,977,706
Simon J. Atkinson · University Of California At Davis$36,072,667
Kim A Stelson · University Of Minnesota-Twin Cities$34,691,036
Larry S. Schlesinger · Texas Biomedical Research Institute$33,714,486
Tim A Bertram · Wake Forest University School Of Medicine$30,163,580

Research focus

RegenerativeRepairedMyocardialRecurrenceMyocardial InfarctionRegenerative MedicineImmunohistochemistryHolter ElectrocardiographyExtracellular MatrixRattusHeart FailureAcute Myocardial InfarctionMyocardiumPatient PopulationArrhythmiaEchocardiographyFamily SuidaeHistologyCathetersEnvironmentCellsMinimally InvasiveBiocompatible MaterialsSmall Business Innovation Research Grant

Grant awards (6)

Pivotal Preclinical Studies of Novel Infusible ECM for Treating Acute MI$1,440,231

R44 · FY2024 · HL · contact PI

Pivotal Preclinical Studies of Novel Infusible ECM for Treating Acute MI$552,109

R44 · FY2023 · HL · contact PI

New infusible ECM hydrogel for treating acute myocardial infarction$791,543

R43 · FY2020 · HL · contact PI

Phase II: Percutaneous deliverable biomaterial for treating myocardial infarction$720,276

R44 · FY2014 · HL · contact PI

Phase II: Percutaneous deliverable biomaterial for treating myocardial infarction$1,339,549

R44 · FY2013 · HL · contact PI

Percutaneous deliverable biomaterial for treating myocardial infarction$496,930

R43 · FY2011 · HL · contact PI